Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Top Cited Papers
- 20 May 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (20), 1885-1898
- https://doi.org/10.1056/nejmoa2102214
Abstract
Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa. We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×1010 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization assays against the original D614G virus and the B.1.351 variant. The primary end points were safety and efficacy of the vaccine against laboratory-confirmed symptomatic coronavirus 2019 illness (Covid-19) more than 14 days after the second dose. Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively. Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients. In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], −49.9 to 59.8). Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, −76.8 to 54.8). The incidence of serious adverse events was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-017710)
- South African Medical Research Council (96167)
- U.K. Research and Innovation (MC_PC_19055)
- UK National Institute for Health Research
This publication has 20 references indexed in Scilit:
- How to Leverage the Medicare Program for a COVID-19 Vaccination CampaignJAMA, 2021
- SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predispositionJCI Insight, 2020
- Understanding COVID-19 vaccine efficacyScience, 2020
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- The Development of COVID-19 VaccinesJAMA, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)JAMA, 2020
- COVID-19 vaccine development pipeline gears upThe Lancet, 2020
- Developing Covid-19 Vaccines at Pandemic SpeedThe New England Journal of Medicine, 2020